Try our Advanced Search for more refined results

HsingChing Hsu v. Puma Biotechnology, Inc. et al

  1. August 04, 2022

    Robbins Geller Nabs $13.5M In Puma Biotech Investor Suit

    A California federal judge has granted lawyers with Robbins Geller Rudman & Dowd LLP more than $13.5 million in attorney fees along with final approval for a $54.2 million settlement for investors who alleged Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment.

  2. December 14, 2021

    Puma Biotech Investors Ink $54M Deal Over Drug Statements

    Investors alleging that Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment, causing the biopharmaceutical company's share price to drop, asked a California federal judge Monday to preliminarily approve a $54.2 million proposed settlement, telling the judge the deal represents a complete recovery for the class.

  3. July 29, 2019

    Puma Biotech Says Liability Still Unsettled In Stock-Drop Row

    Puma Biotechnology Inc. told a California federal judge last week that investors who scored a partial jury win on stock-drop claims are trying to breeze past the fact that the jury's verdict didn't resolve liability or damages.

  4. February 05, 2019

    Puma Biotech Misled Investors About Cancer Trial, Jury Says

    A California federal jury has determined that Puma Biotechnology Inc. made misrepresentations in one of four contested statements about the results of a clinical trial involving a breast cancer treatment, awarding investors damages worth $4.50 per share.

  5. January 23, 2018

    Video-Averse Plaintiffs' Atty Has Been Abusive, Puma Says

    Attorneys representing Puma Biotechnology Inc. in a class action suit brought by investors told the court Monday that it should allow them to film an attorney for the investors during a deposition of Puma's CEO, saying the attorney had been "disrespectful, unprofessional and abusive" in past depositions.

  6. January 17, 2018

    Puma Biotech Investors Say Depo Camera Is Meant To Harass

    Camera-shy lawyers representing Puma Biotechnology Inc. investors on Tuesday asked a California federal judge to block a Latham & Watkins LLP defense team from training a video camera on them at an upcoming deposition.

  7. December 11, 2017

    Puma Biotech Investor Class Certified In Stock Drop Case

    A California federal judge on Friday granted class certification to Puma Biotechnologies Inc. investors in a stock drop suit accusing the company of misrepresenting the effectiveness of a breast cancer treatment called neratinib.

  8. July 26, 2017

    Cancer-Drug Maker Loses 2nd Bid To Duck Stock-Drop Suit

    A California federal judge on Tuesday rejected a biotechnology company's request to dismiss an updated securities fraud lawsuit against it over allegedly misleading results in a clinical trial for its cancer drug, saying the new allegations clear the legal bar for stock-drop class actions.

  9. March 15, 2017

    Puma Biotech Investors Seek Class Cert. In Stock-Drop Case

    Puma Biotechnology Inc. investors who lost money when clinical trial results undercut the biopharmaceutical company's prior statements about a cancer drug it was developing asked a California federal court Wednesday for class status and to have Robbins Geller Rudman & Dowd LLP represent them.

  10. October 03, 2016

    Puma Investors' Suit Lives As Judge Dings Judicial Notice

    Puma Biotechnology Inc. will have to face a proposed class action for allegedly misleading investors about a breast cancer drug, a California federal judge ruled in an order Friday that also included some criticism for the way defense attorneys have employed judicial notice requests.